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Acne vulgaris is a skin disorder of the sebaceous follicles, involving hyperkeratinization and perifollicular inﬂam-
mation. Matrix metalloproteinases (MMP) have a predominant role in inﬂammatory matrix remodeling and hyper-
proliferative skin disorders. We investigated the expression of MMP and tissue inhibitors of MMP (TIMP) in facial
sebum specimens from acne patients, before and after treatment with isotretinoin. Gelatin zymography and West-
ern-blot analysis revealed that sebum contains proMMP-9, which was decreased following per os or topical treat-
ment with isotretinoin and in parallel to the clinical improvement of acne. Sebum also contains MMP-1, MMP-13,
TIMP-1, and TIMP-2, as assessed by ELISA and western blot, but only MMP-13 was decreased following treatment
with isotretinoin. The origin of MMP and TIMP in sebum is attributed to keratinocytes and sebocytes, since we
found that HaCaT keratinocytes in culture secrete proMMP-2, proMMP-9, MMP-1, MMP-13, TIMP-1, and TIMP-2. SZ95
sebocytes in culture secreted proMMP-2 and proMMP-9, which was also conﬁrmed by microarray analysis. Is-
otretinoin inhibited the arachidonic acid-induced secretion and mRNA expression of proMMP-2 and -9 in both cell
types and of MMP-13 in HaCaT keratinocytes. These data indicate that MMP and TIMP of epithelial origin may be
involved in acne pathogenesis, and that isotretinoin-induced reduction in MMP-9 and -13 may contribute to the
therapeutic effects of the agent in acne.
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Acne vulgaris is the most common skin disorder, initiated
due to sebaceous gland hyperactivity and hyperseborrhea,
abnormal hyperproliferation of ductal keratinocytes and
keratinization of the acroinfundibular epithelium of the se-
baceous follicle, and inflammatory signaling giving rise to
microcomedones (Zouboulis, 2001a). Sebum consists prin-
cipally of triglycerides, which are subsequently hydrolyzed
to yield free fatty acids and glycerol, and in addition sebum
also contains keratinocytes, microorganisms, neutrophils,
and macrophages (Toyoda and Morohashi, 2001). Although
individual acne lesions spontaneously regress, persistent
cases of acne vulgaris often require pharmacological inter-
vention.
Pharmacotherapy of acne vulgaris includes a variety of
compounds, with the retinoids possessing a prevailing po-
sition (Zouboulis, 2001c). Among the retinoic acid (RA) an-
alogues that have been established for systemic and/or
topical treatment of hyperproliferative skin disorders, in-
flammatory diseases, and cancer (Orfanos et al, 1997;
Zouboulis, 2001c), the non-aromatic retinoid isotretinoin
(13-cis-RA) secures effective treatment of acne, but it may
also cause adverse and toxic effects (Zouboulis and Orfa-
nos, 2000). The antiproliferative effect of isotretinoin on se-
bocytes is manifested through its isomerization into all-
trans-RA and binding to nuclear RA receptors (Zouboulis,
2001b; Tsukada et al, 2002). Isotretinoin displays key reg-
ulatory functions on epidermal growth and differentiation
(Fisher and Voorhees, 1996) but the cellular and biochem-
ical alterations associated with them are not fully clarified.
Isotretinoin has been reported to affect matrix metal-
loproteinases (MMP) (Jimenez et al, 2001; Zhu et al, 2001;
Devy et al, 2002), a family of Zn-dependent metal-
lopeptidases that has been implicated in skin biology dur-
ing inflammatory matrix remodeling, neovascularization,
wound healing, and malignant transformation. Thus, it ap-
pears that MMP have a predominant role in pathological
manifestations of diseases treated with retinoids, such as
hyperproliferative skin disorders, inflammatory diseases,
and cancer (Orfanos et al, 1997). MMP degrade extracel-
lular matrix molecules during physiological and pathological
tissue remodeling (Visse and Nagase, 2003). The MMP gene
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family encodes for several proenzymes (proMMP) with
common and distinctive structural and functional proper-
ties, classified as: (a) collagenases 1–4 (MMP-1, -8, -13 and
-18, respectively), (b) gelatinases A and B (MMP-2 and -9,
respectively), (c) stromelysins 1–3 (MMP-3, -10, and -11,
respectively), (d) matrilysins 1–2 (MMP-7 and -26, respec-
tively), (e) membrane type 1–6 (MT-MMP: MMP-14, -15, -16,
-17, -24, and -25, respectively), and (f) various others
(MMP-12, -19, -20, -21, -23, -27, and -28) (Visse and
Nagase, 2003). The activity of MMP is tightly regulated dur-
ing proMMP expression (Stetler-Stevenson et al, 1993) and
by proteolytic activation of secreted latent MMP (Cao et al,
1995). MMP, both in latent and activated form, are also
regulated by the formation of stoichiometric 1:1 complexes
with specific inhibitors, known as tissue inhibitors of met-
alloproteinases (TIMP) (Stetler-Stevenson et al, 1993). Four
TIMP have been identified, but inactivation of MMP by TIMP
is predominantly attributed to TIMP-1 and -2. TIMP-1 forms
high-affinity, non-covalent complexes with latent MMP-9
and active MMP-1, -3, and -9, whereas TIMP-2 forms com-
plexes with latent and active MMP-2 (Gomez et al, 1997).
TIMP-1/proMMP-9 and TIMP-2/proMMP-2 complexes are
also capable of inhibiting active MMP through the unoccu-
pied N-terminal domain of the inhibitor in the complex (Itoh
et al, 1995).
The effect of isotretinoin on MMP, however, is contradic-
tory, since there is evidence suggesting that retinoids in-
crease (Jimenez et al, 2001), reduce (Neuville et al, 1999;
Leville et al, 2000; Axel et al, 2001; Frankenberger et al,
2001; Tsang and Crowe, 2001; Devy et al, 2002; Osteen
et al, 2002), or do not affect (Zhu et al, 2001) the activity or
gene expression of MMP in various human and animal bi-
ological systems and cell lines. Furthermore, there is no
report concerning the presence of MMP in lesions of acne
vulgaris or the effect of isotretinoin treatment on MMP in
sebum of acne patients.
In this study, we investigated the presence of gelatin-
ases, collagenases, and TIMP in sebum samples of facial
lesions from patients with acne vulgaris, as well as in cul-
tures of HaCaT keratinocytes and SZ95 sebocytes, and the
effect of isotretinoin in these parameters. We found that
proMMP-9, MMP-1, MMP-13, and TIMP-1 and TIMP-2 are
present in the sebum of facial lesions from acne patients,
possibly originating from keratinocytes and sebocytes, and
that MMP-9 and -13 are reduced in parallel to treatment
with isotretinoin and the clinical improvement of the lesions.
Results
Acne sebum samples
Keratinocyte and bacteriologic ﬁndings Examination of se-
bum specimens, diluted to contain the same amount of
protein per mL, revealed the presence of keratinocytes un-
der a light microscope in all 0 d samples from 59 patients.
After 60 d of topical (0.05% once daily) or systemic (1 mg
per kg per d per os) treatment with isotretinoin, examination
of 60 d sebum samples showed that keratinocytes were
present only in 11 of 59 patients and in considerably di-
minished numbers. Bacterial cultures of sebum specimens
revealed the presence of P. acnes (propionibacterium
acnes) in all 0 d samples and of Staphylococcus epider-
midis in two samples. No other microorganisms were de-
tected in 0 d samples. Furthermore, no bacteria could be
detected in any of the 60 d samples.
Gelatinase activity Gelatin zymography analysis revealed
that 0 d sebum samples of facial acne lesions express gel-
atinase activity, which produced major lysis bands (Fig 1a),
which comigrated as purified proMMP-9 (92.0 kDa). Gela-
tinolytic activity was completely inhibited by developing the
zymograms in the presence of the metal chelators Na2EDTA
(20 mM) or 1,10-phenanthroline (4 mM), but was unaffected
by N-ethyl-maleimide (5 mM) (data not shown), indicative of
a metalloproteinase, corresponding to proMMP-9. Zymo-
graphy analysis of samples obtained at 30 and 60 d fol-
lowing systemic per os or topical treatment with isotretinoin
(Fig 1a), indicated that gelatinolytic activity was reduced
in relation to the duration of treatment. Quantification of
zymography lysis bands of all acne samples tested, using
a computer-assisted image analysis program (Fig 1b), re-
vealed that the decrease in gelatinolytic activity was statis-
Figure1
Gelatinase activity is reduced in sebum of facial acne lesions in a
time-dependent manner during therapy with isotretinoin. (a) Rep-
resentative gelatin zymography in aliquots of sebum (5 mg of protein)
during systemic per os (lanes 4–6) and topical (lanes 7–9) treatment with
isotretinoin. Arrows indicated pre-stained standard protein molecular
weight markers (lane 1): phosphorylase b (97.4 kDa), bovine serum
albumin (66.2 kDa), L-glutamic dehydrogenase (55.0 kDa), and oval-
bumin (42.7 kDa). Lane 2: migration of purified promatrix metal-
loproteinase (proMMP)-2 (72 kDa); lane 3: proMMP-9 (92 kDa); lanes 4
and 7: 0 d samples; lanes 5 and 8: 30 d samples; lanes 6 and 9: 60 d
samples. (b) Quantitative analysis of gelatinolytic activity in sebum fol-
lowing systemic per os (n¼ 23) or topical (n¼ 36) treatment of acne
patients with isotretinoin using a computer-supported image analysis
program. Each bar represents the mean  SD from n specimens. Sta-
tistical significance: po0.05; po0.01 as compared with 0 d sam-
ples, which were regarded as 100% gelatinolytic activity.
674 PAPAKONSTANTINOU ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
tically significant at 30 d (po0.05) and 60 d (po0.01) of
treatment, wherreas the route of administration of is-
otretinoin did not influence the decrease in gelatinase
activity.
Detection of gelatinases and effect of isotretinoin treat-
ment Using human MMP-2 antiserum, we found that there
was no immunoreactivity for MMP-2 in 0 and 30 d sebum
samples (Fig 2a, lanes 2 and 3). Using human MMP-9 an-
tiserum, three distinct immunoreactive bands with Mr 94.0,
78.0, and 64.0 kDa were revealed in 0 d sebum samples by
western blotting (Fig 2a, lane 4). The upper band corre-
sponds to proMMP-9 and comigrated as reference sample
of proMMP-9 (94.0 kDa) that has been previously fully char-
acterized from human periprosthetic tissue of loose hip
endoprostheses (Syggelos et al, 2001). The two lower
immunoreactive bands may be attributed to endogenous
activation or degradation of the 94.0 kDa proenzyme, due to
the experimental conditions adopted (Kerkela and Sa-
arialho-Kere, 2003). The fact that the 78.0 and 64.0 kDa
proteins identified by western blotting could not be visual-
ized by gelatin zymography indicates that these proteins do
not possess gelatinolytic activity. Treatment with isotretinoin
for 30 d resulted in reduced expression of all the above-
described bands of MMP-9 (Fig 2a, lane 5, per os treat-
ment). Quantification of the chemiluminescence of each
band using a computer-assisted image analysis program
revealed that the observed reduction was statistically sig-
nificant at 30 d of treatment (po0.01, po0.05, po0.01,
respectively, for each band) (Fig 2b), whereas the route of
administration of isotretinoin did not influence the decrease
in MMP-9 immunoreactivity (results not shown).
Effect of isotretinoin on gelatinases in vitro In order to in-
vestigate whether isotretinoin has a direct inhibitory effect
on the activity of gelatinases, we subjected sebum samples
(0 d, corresponding to 5 mg protein) or commercially avail-
able proMMP-2 and -9 (1 ng) to gel electrophoresis, re-
moved sodium dodecyl sulfate (SDS), and conducted
gelatin lysis of the gels by incubating in enzyme buffer in
the presence of isotretinoin (0–1 mM) for 18 h, at 371C.
Alternatively, we pre-incubated sebum samples (0 d, cor-
responding to 5 mg protein) or commercially available proM-
MP-2 and -9 (1 ng), with isotretinoin (0–1 mM) for 30 min
at room temperature, subjected samples to gel elect-
rophoresis, removed SDS, and conducted to gelatin lysis
of the gels by incubating in enzyme buffer for 18 h, at 371C.
Analysis of the results revealed that neither the presence of
isotretinoin during gelatin zymography (results not shown)
nor pre-treatment of the samples with isotretinoin for 30 min
influenced proMMP-9 present in 0 d sebum samples (Fig
3a) or purified latent gelatinases (Fig 3b).
Detection of collagenases by western blotting and effect of
isotretinoin treatment Using polyclonal antibodies for MMP-
1, three distinct immunoreactive bands were revealed in 0 d
sebum samples by western blotting (Fig 4a, lane 2), with Mr
52.4, 45.0, and 43.5 kDa as estimated using molecular
weight markers. These bands corresponded to purified hu-
man MMP standards: proMMP-1 (52.4 kDa) and fully active
MMP-1 (45.0 and 43.5 kDa), respectively, in comparison
with reference samples of proMMP-1 and MMP-1 (Fig 4a,
lane 1), which have been previously fully characterized from
human periprosthetic tissue of loose hip endoprostheses
(Syggelos et al, 2001). The ratio of latent to active MMP-1
was approximately 8/1. Treatment with isotretinoin for 30 or
60 d did not affect the expression of latent or active MMP-1
(Fig 4a, lane 3, topical treatment, 30 d).
Using polyclonal antibodies for MMP-13, two distinct
immunoreactive bands were revealed in 0 d sebum samples
by western blotting (Fig 4b, lane 1), with Mr 65.0 and 52.0
kDa as estimated using molecular weight markers. These
bands corresponded to purified human MMP standards:
proMMP-13 and fully active MMP-13, respectively, in com-
parison with reference samples of proMMP-13 and MMP-
13 (Fig 4b, lane 3), which have been previously fully char-
acterized from human periprosthetic tissue of loose hip
endoprostheses (Syggelos et al, 2001). The ratio of latent to
active MMP-13 was approximately 1/2. Treatment with is-
otretinoin for 30 or 60 d significantly reduced the expression
of latent or active MMP-13 (Fig 4b, lane 3, topical treatment,
30 d).
Determination of collagenases by ELISA and effect of is-
otretinoin treatment Measurement of MMP-1 and -13 by
Figure 2
Western blot analysis of gelatinases in sebum samples indicates
the presence of matrix metalloproteinase (MMP)-9 but not of
MMP-2. (a) Representative western blot analysis of sebum during sys-
temic per os treatment with isotretinoin. Analysis was performed using
human MMP-2 antiserum: lane 1: purified promatrix metalloproteinase
(proMMP)-2 (72.0 kDa), lane 2, 0 d sample; lane 3, 30 d sample, and
human MMP-9 antiserum: lane 4, 0 d sample; lane 5, 30 d sample.
Arrow on the right indicates the reference sample of proMMP-9 (94.0
kDa), which has been previously fully characterized from human peri-
prosthetic tissue of loose hip endoprostheses. Arrows on the left in-
dicate molecular weight size markers (phosphorylase b, 97.4 kDa;
bovine serum albumin, 66.2 kDa; L-glutamic dehydrogenase, 55.0 kDa).
(b) Quantitative analysis of western blots of MMP-9 immunoreactive
bands of sebum following systemic per os treatment of acne patients
(n¼ 23) with isotretinoin for 30 d, using a computer-supported image
analysis program. Each bar represents the mean  SD from n spec-
imens. Statistical significance: po0.05; po0.01 as compared with
0 d samples.
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ELISA revealed that sebum samples expressed both colla-
genases (Table I, Fig 4c). In 0 d sebum samples of patients
grouped for per os treatment, MMP-1 was 105  20 pg per
mg of protein and MMP-13 was 92  8 pg per mg of protein.
Similar values were obtained in 0 d sebum samples from
patients grouped for topical administration. MMP-1 was not
affected following treatment with isotretinoin for 60 d, irre-
spective of the route of administration. In contrast, MMP-13
was significantly reduced by about 55% and 58% after 30
and 60 d of per os treatment with isotretinoin, respectively
(po0.02). This effect was also evident after topical admin-
istration of isotretinoin, resulting in a significant decrease of
MMP-13 by approximately 50% and 60% after 30 and 60 d
of treatment with isotretinoin, respectively (po0.02).
Production of TIMP Measurement of TIMP-1 and -2 by
ELISA in 0 d sebum samples of patients grouped for per os
administration indicated the presence of TIMP-1 (405  198
pg per mg protein) and TIMP-2 (219  84 pg per mg protein)
(Fig 5). Similar values were obtained in 0 d sebum samples
from patients grouped for topical administration. Treatment
with isotretinoin did not influence the production of TIMP,
irrespective of the route of administration (Fig 5).
HaCaT keratinocyte and SZ95 sebocyte cultures In order
to elucidate the origin of MMP and TIMP in sebum samples,
we examined their expression in HaCaT keratinocytes and
SZ95 sebocyte cultures after 12, 24, and 48 h of incubation
with or without arachidonic acid, in the presence and in the
absence of isotretinoin. Arachidonic acid, a pro-inflamma-
tory essential fatty acid, was included in the study since it
has also been reported to induce sebaceous lipid synthesis
(Wro´bel et al, 2003) and may be involved in acne patho-
Figure4
Matrix metalloproteinase (MMP)-1 and MMP-13 are expressed in
sebum of facial acne lesions, and MMP-13 expression is reduced
during isotretinoin treatment. (a) Representative western blot anal-
ysis of sebum during topical treatment with isotretinoin using polyclonal
antibodies for MMP-1. Lane 1 and arrows on the left: immunoreactive
bands from reference samples of promatrix metalloproteinase (proM-
MP)-1 (52.4 kDa) and MMP-1 (45.0 and 43.5 kDa), which have been
fully characterized previously from human periprosthetic tissue of loose
hip endoprostheses. Lane 2: immunoreactive bands of 0 d sebum
samples. Lane 3: immunoreactive bands of 30 d sebum samples fol-
lowing topical treatment with isotretinoin. Lane 4 and arrows on the
right indicate protein molecular weight markers: bovine serum albumin
(66.2 kDa), ovalbumin (42.7 kDa), and soybean trypsin ihibitor (21.5
kDa). (b) Representative western blot analysis of sebum during topical
treatment with isotretinoin using polyclonal antibodies for MMP-13.
Lane 1 and arrows on the left indicate protein molecular weight mark-
ers: bovine serum albumin (66.2 kDa), ovalbumin (42.7 kDa) and soy-
bean trypsin ihibitor (21.5 kDa). Lane 2: immunoreactive bands of 0 d
sebum samples. Lane 3: immunoreactive bands of 30 d sebum sam-
ples following topical treatment with isotretinoin. Lane 4 and arrows on
the right: immunoreactive bands from reference samples of proMMP-
13 (65.0 kDa) and MMP-13 (52.0 kDa) from human periprosthetic tis-
sue. (c) Aliquots of sebum samples were assessed for MMP-1 and
MMP-13 by ELISA, prior to and following per os (n¼23) and topical
(n¼36) treatment of acne patients with isotretinoin, for 30 and 60 d.
Each bar represents the mean  SD of triplicate determinations from n
samples. Statistical significance: po0.02 as compared with 0 d
sample.
Figure 3
Isotretinoin does not influence gelatinase in vitro. (a) Sebum sam-
ples (0 d, corresponding to 5 mg protein) were preincubated with is-
otretinoin (0–1 mM) for 30 min at room temperature and subjected to
gelatin zymography, as described in Materials and Methods. Lane 4, 0
mM; lane 5, 0.01 mM; lane 6, 0.1 mM; lane 7, 1 mM. (b) Commercially
available purified promatrix metalloproteinase (proMMP)-2 and proM-
MP-9 (1 ng protein) were treated as above. ProMMP-2: lane 4, 01 mM;
lane 5, 1 mM. ProMMP-9: lane 6, 0.1 mM; lane 7, 1 mM, lane 7. Arrows
and lane 1 indicate molecular weight markers: phosphorylase b (97.4
kDa), bovine serum albumin (66.2 kDa), L-glutamic dehydrogenase
(55.0 kDa), ovalbumin (42.7 kDa), and aldolase (40.0 kDa). Lane 2: pu-
rified proMMP-2 (72 kDa) and lane 3 purified proMMP-9 (92 kDa).
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genesis (Zouboulis et al, 2005). Cells cultured in the pres-
ence of arachidonic acid will better represent follicular ker-
atinocytes of acne patients than HaCaT keratinocytes not
under inflammatory challenge.
MMP and TIMP mRNA expression in SZ95 sebocytes The
mRNA expression of MMP and TIMP in SZ95 sebocytes
was investigated by analyzing the results of expression
profiles generated from untreated SZ95 sebocytes, follow-
ing complementary DNA (cDNA) microarrays and image
analysis (Fig S1). Expression was judged by signal detect-
ability using a negative control sample present on each ar-
ray. The average proportion of negative samples that was
expressed below the probe’s signal threshold across the
replicate experiments indicated the detectability. The level
of 0.9 was used to judge expression of genes. For each
cDNA’s expression signal, the log ratio (base 2) of this signal
was computed with the median expression signal of all
15,657 cDNA on the array. We found that while gelatinases
were expressed, mRNA for collagenases MMP-1 and -13 as
well as for TIMP-2 was not detected (Table I). Furthermore,
SZ95 sebocytes expressed with high probability (p40.95)
mRNA for MMP-7, -14, -15, -21, and -24 (eventually MMP-3
and -11, too) as well as for TIMP-3 and -4, whereas they did
not express mRNA for MMP-10, -12, -16, -19, -20, -25, -26,
-27, and -28 (Fig S1). Caution should, however, be exer-
cised in interpreting these results, since some of the above-
mentioned MMP and TIMP-2 that could not be detected by
cDNA microarrays may be expressed if they are examined
by more sensitive methods such as quantitative PCR.
Gelatinase activity Gelatin zymography analysis revealed
that both HaCaT keratinocytes and SZ95 sebocytes, after
24 h in culture, secreted gelatinase activity, which produced
two major lysis bands (Fig 6a and c, respectively, Table I).
The upper band comigrated as commercially available
proMMP-9, with Mr corresponding to 87.0 kDa. The lower
band comigrated as commercially available proMMP-2,
with Mr corresponding to 68.0 kDa. In HaCaT keratinocytes,
the minor lysis band with Mr 65.0 kDa, comigrating as
commercially available MMP-2, may represent activation of
proMMP-2. In SZ95 sebocytes, minor lysis bands with
Mr487.0 kDa may be attributed to disulfide polymers of
MMP molecules. Gelatinolytic activity was completely in-
hibited by developing the zymograms in the presence of the
metal chelators Na2EDTA (20 mM) or 1,10-phenanthroline
(4 mM), but was unaffected by N-ethyl-maleimide (5 mM)
(Fig 6a and c), indicating that the activity is due to metal-
Table I. Expression of collagenases, gelatinases, and TIMP in acne sebum, HaCaT keratinocytes, and SZ95 sebocytes as detected




HaCaT keratinocytes SZ95 sebocytes
Proteins mRNA Proteins mRNA
Untreated Iso Untreated AA Iso Untreated AA Iso Untreated AA Iso Untreated AA Iso
Collagenases
MMP-1 D $ D " $ D " $ ND ND ND ND ND ND
MMP-13 D # D $ # c D "c # ND ND ND ND ND ND
Gelatinases
MMP-2a ND ND D " #b D " #b,c D " #b D " #b,c
MMP-9a D # D " #b D " # D " #b D " #b
TIMP
TIMP-1 D $ D " $ D " $ ND ND ND ND ND ND
TIMP-2 D $ D $ $ — — — ND ND ND — — —
aProteins and/or enzyme activity.
bReduction in the arachidonic acid-treated samples only.
cNot statistically significant.
Iso, isotretinoin treated; AA, arachidonic acid treated; D, detected; ND, not detected; $ , not affected by treatment; # , reduced by treatment; " ,
increased by treatment; —, not examined; TIMP, tissue inhibitors of MMP, MMP, matrix metalloproteinases.
Figure 5
Tissue inhibitor of matrix metalloproteinase (TIMP)-1 and -2 are
expressed in sebum samples of facial acne lesions but are not
influenced during isotretinoin treatment. TIMP were measured by
ELISA in aliquots of sebum specimens (2 mg of protein) during per os
treatment of 23 acne patients and topical treatment of 36 acne patients
with isotretinoin for 0, 30, and 60 d. Each bar represents the
mean  SD of triplicate determinations from n specimens.
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loproteinase and excluding serine or cystein proteinase ac-
tivity, respectively. These results indicate that the 2 major
lysis bands described above are MMP, corresponding to
proMMP-9 and -2, respectively (Karakiulakis et al, 1988;
Visse and Nagase, 2003). Quantification of zymography
lysis bands obtained from all cell cultures tested revealed
that arachidonic acid induced the secretion of MMP-9 by
45% (po0.02) and of MMP-2 by 30% (po0.05) in HaCaT
keratinocytes, and by 300% (po0.01) and 25% (po0.05),
respectively, in SZ95 sebocytes. Zymography analysis of
samples obtained at 12 or 48 h in culture revealed similar
profiles for both cell lines (results not shown), as for 24 h in
culture. Isotretinoin (at 108 and 107 M) did not affect gel-
atinolytic activity in keratinocytes or SZ95 sebocytes at any
time point (Fig 6, for 24 h in culture). In both cell lines,
however, isotretinoin reduced the arachidonic acid-induced
secretion of MMP-2 and -9 to levels comparable to controls
(po0.05 to 0.01) (Figs 6b and d).
Secretion of collagenases Measurement of MMP-1 and -13
by ELISA revealed that HaCaT keratinocytes secreted both
MMP-1 (29.8  2.6 ng per mg protein after 48 h of incuba-
tion, Fig 7) and MMP-13 (48.1  2.9 ng per mg protein after
48 h of incubation; data not shown). In contrast, neither
collagenase could be detected in SZ95 sebocytes (Table I).
Arachidonic acid significantly increased MMP-1 in HaCaT
keratinocytes in a time-dependent manner (Fig 7), but did
not influence MMP-13 (data not shown). Isotretinoin (at 108
and 107 M) did not influence the basal (Fig 7) or the
arachidonic acid-induced MMP-1 secretion in HaCaT ker-
atinocytes up to 48 h of incubation (data not shown). Is-
otretinoin appeared to reduce MMP-13 production in
HaCaT keratinocytes, in a time- and concentration-depend-
ent manner (14%–20% reduction), but this effect was not
statistically significant (data not shown).
Figure7
Matrix metalloproteinase (MMP)-1 is secreted by HaCaT keratin-
ocytes and upregulated by arachidonic acid. Aliquots of supernat-
ants from HaCaT keratinocytes incubated for 12–48 h were assessed
for MMP-1 by ELISA. Each bar represents the mean  SD of triplicate
determinations from four assays. Iso, isotretinoin, AA, arachidonic acid
(104 M). Statistical significance: po0.05; po0.02, as compared
with control (untreated cells).
Figure6
HaCaT keratinocytes and SZ95 sebocytes secrete promatrix met-
alloproteinase pro(MMP)-2 and -9, which are upregulated by
arachidonic acid and downregulated by isotretinoin. Representa-
tive gelatin zymographies from the cell culture medium of HaCaT ker-
atinocytes (a) and SZ95 sebocytes (c), incubated for 24 h. Lanes 1:
untreated (control), lanes 2: arachidonic acid (AA; 104 M), lanes 3:
isotretinoin (Iso; 108 M), lanes 4: isotretinoin (107 M), lanes 5:
arachidonic acid (104 M)þ isotretinoin (108 M), lanes 6: AA (104
M)þ isotretinoin (107 M), lanes 7: untreated (control), lanes 8: N-ethyl-
maleimide (NEM, 5 mM), lanes 9: Na2EDTA (EDTA, 20 mM), and lanes
10: 1,10-phenanthroline (Phen, 4 mM). Arrows indicate proMMP-9 (92
kDa), proMMP-2 (72 kDa), and MMP-2 (64 kDa). Quantitative analysis
of the gelatinolytic activity present in the culture media from cell cul-
tures of HaCaT keratinocytes (b) and SZ95 sebocytes (d). Each bar
represents the mean  SD from 4 zymograms. Statistical significance:
po0.05; po0.02, po0.01, as compared with control (untreated
cells) ( ), or with AA alone [ ]. Iso, isotretinoin; AA, (104 M).
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Secretion of TIMP Measurement of TIMP by ELISA indicat-
ed the presence of TIMP-1 (16.7  4.2 ng per mg protein
after 48 h of incubation) and TIMP-2 (39.4  5.5 ng per mg
protein after 48 h of incubation, data not shown) in HaCaT
keratinocytes, whereas neither TIMP could be detected in
SZ95 sebocytes (Table I, Fig S1). Arachidonic acid (104 M),
significantly increased TIMP-1 in HaCaT keratinocytes in a
time-dependent manner (63% increase after 12 h to 132%
increase after 48 h of incubation, po0.01), but did not in-
fluence TIMP-2 (data not shown). Isotretinoin (at 108 and
107 M) did not influence either basal TIMP or the
arachidonic acid-induced TIMP-1 production in HaCaT ker-
atinocytes up to 48 h of incubation (data not shown).
Gene expression of MMP and TIMP-1 Gene expression of
MMP and TIMP-1 was investigated by RT-PCR analysis.
MMP-1, -13, -2, -9, and TIMP-1 mRNA were expressed in
HaCaT keratinocytes after 24 h of incubation (Fig 8, Table I),
and MMP-2 and -9 in SZ95 sebocytes (Table I). Glyceral-
dehyde-3-phosphate dehydrogenase gene (GAPDH) was
used as the internal standard. Quantification of chemilumi-
nescence was performed using a computer-assisted image
analysis program. The ratio of chemiluminescence of each
parameter measured to GAPDH revealed the following: (a)
HaCaT keratinocytes: The gene expression of MMP-1 was
enhanced by arachidonic acid (104 M) by 42%, (po0.05),
but was not affected by isotretinoin (107 M). MMP-13 (Fig
8, inset) was enhanced by arachidonic acid by 37% and
both basal- and arachidonic acid-induced gene expres-
sions were downregulated by isotretinoin by approximately
50% (po0.05). Arachidonic acid enhanced MMP-2 by 37%
(po0.05), and arachidonic acid-induced gene expression
was downregulated by isotretinoin by 33%. MMP-9 was
enhanced by arachidonic acid by 36% (po0.05), and both
basal- and arachidonic acid-induced gene expression were
downregulated by isotretinoin by 42% and 49%, respec-
tively, (po0.05). TIMP-1 was enhanced by arachidonic acid
by 60% (po0.05) but was not affected by isotretinoin. (b)
SZ95 sebocytes: Arachidonic acid enhanced the gene ex-
pression of MMP-2 by 38% (po0.05), and isotretinoin
downregulated the arachidonic acid-induced gene expres-
sion by 48% (po0.05). Similarly, arachidonic acid enhanced
MMP-9 by 42% (po0.05), and isotretinoin downregulated
the arachidonic acid-induced gene expression by 44%
(po0.05).
With the exception of MMP-13 (Fig 8, inset), however,
caution should be exercised in interpreting the changes in
gene expression of other MMP and TIMP-1 in treated Ha-
CaT keratinocytes and SZ95 sebocytes, as detected by
semi-quantitative RT-PCR, since the magnitude of changes
in expression relative to GAPDH were less than 2-fold,
which is generally not considered to be significant, despite
the statistically significant differences in the relative chemi-
luminescence values obtained from the ethidium bromide-
stained gels.
Discussion
In this study, we investigated the involvement of MMP and
TIMP in sebum from facial acne lesions, and the effect of
isotretinoin treatment on these molecules associated with
inflammatory matrix responses. Gelatin zymography and
western blot analysis indicated the presence of gelatinases
in sebum, attributed mainly to proMMP-9, whereas ELISA
and western blot analysis revealed the presence of colla-
genases MMP-1, mainly as proMMP-1 and MMP-13, both
in latent and active forms. The expression of TIMP-1 and -2
was also demonstrated using ELISA, and their presence
may account for the existence of MMP mainly in the latent
form.
The predominant types of cells that could be identified
under light microscopy of sebum specimens were keratin-
ocytes, P. acnes, and Staphylococcus epidermidis. Light
microscopy of sebum samples revealed that keratinocytes
and bacteria count decreased with progression of treatment
with isotretinoin.
The cell source of MMP and TIMP in sebum that we
observed cannot be attributed to P. acnes or other micro-
organisms found in the pilosebaceous unit, such as
Pityrosporum ovale, Propionibacterium granulosum, and
S. epidermidis, since these bacteria do not comprise a
source of MMP activity. Therefore, the cell origin of MMP
and TIMP in sebum is likely to be keratinocytes. Sebocytes
may also be responsible for MMP and TIMP expression in
sebum, since the latter is a holocrine product of sebocytes
(Zouboulis et al, 2003). The possibility that keratinocytes
and sebocytes may comprise the cell source for MMP and
TIMP in sebum is supported by our findings that HaCaT
keratinocytes in culture express and secrete proMMP-2,
proMMP-9, MMP-1, MMP-13, and TIMP-1 and TIMP-2, and
that SZ95 sebocytes in culture express and secrete pro-
Figure 8
HaCaT keratinocytes express mRNA for matrix metalloproteinase
(MMP) and tissue inhibitor of matrix metalloproteinase (TIMP)-1,
and isotretinoin inhibits MMP-9 and MMP-13 de novo and
arachidonic acid-induced mRNA. Quantitative analysis of chemilu-
minescence of RT-PCR analyses of HaCaT keratinocytes incubated in
the absence or in the presence of isotretinoin (107 M, 24 h) using
primers for MMP-1, MMP-9, MMP-13, and TIMP-1, as described under
‘‘Materials and Methods’’. Each bar represents the mean  SD from
four assays. Statistical significance: po0.05; AA, arachidonic acid,
104 M; Iso, isotretinoin, 107 M. Inset: Representative analysis of
chemiluminescence of RT-PCR analyses of HaCaT keratinocytes incu-
bated in the absence or in the presence of isotretinoin (107 M, 24 h)
using primers for MMP-13. GAPDH of expected size 263 bp was used
as an internal standard. The expected size of the reaction product for
MMP-13 is indicated by the arrow. Lane 1, DNA ladder (100 bp); lane 2,
untreated; lane 3, AA (104 M); lane 4, isotretinoin (107 M); and lane 5,
AA (104 M) and isotretinoin (107 M).
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MMP-2 and -9, which was also confirmed by cDNA micro-
array analysis. Sebocytes may be a source of other MMP,
which may also contribute to the pathogenesis of
acne. These findings are in agreement with reports that
human keratinocytes of normal or pathological origin pro-
duce or express latent and active gelatinases and TIMP
(Baumann et al, 2000; Fleischmajer et al, 2000; Kobayashi
et al, 2000).
ProMMP-2 was not detected in sebum, even though
both HaCaT keratinocytes and SZ95 sebocytes produced
proMMP-2. This may be attributed to the fact that cells in
culture are not confronted with proteases at the level that
inflammatory human tissue does. In the latter case, the
presence of proteases may lead to deactivation, inhibition,
or destruction of MMP-2 in the diseased human follicle
in vivo. Even though the results from HaCaT keratinocytes
and SZ95 sebocytes in culture are of considerable value,
caution should be exercised in extrapolating the results
from cell cultures to the in vivo situation, since HaCaT cells
are not a model for follicular keratinocytes and differences
may exist in MMP expression between normal and HaCaT
keratinocytes. Thus, the possibility that the cell sources of
sebum MMP and TIMP are follicular keratinocytes remains
to be verified by using tissues of sebaceous follicle and
glands of acne patients.
The prospect that other type of cells associated with
MMP and TIMP production, such as skin fibroblasts or in-
filtrating macrophages in the inflammatory acne lesions,
may comprise the cell source of MMP and TIMP in sebum
should also be considered. In this respect, it has been re-
ported that retinoids reduce the activation of MMP in fib-
roblasts (Overall, 1995) and that tretinoin downregulates
MMP-9 mRNA and protein in alveolar macrophages from
patients with chronic obstructive pulmonary disease (Frank-
enberger et al, 2001) and emphysema (Mao et al, 2003), and
that it reverses upregulation of MMP-13 in human keloid-
derived fibroblasts (Uchida et al, 2003).
The pro-inflammatory essential fatty acid arachidonic
acid significantly induced proMMP-2 and -9 in both cell
types investigated, as well as MMP-1 and TIMP-1 in HaCaT
keratinocytes. The association between arachidonic acid
and MMP and TIMP expression has also been reported for
several cell types and tissues, as e.g., in the human athe-
rosclerotic plaques (Cipollone et al, 2003), in synoviocytes
(Burger et al, 2003), in renal tubular cells (Cussac et al,
2002), and in calvaria and bone marrow cells (Choi et al,
2003).
Topical or systemic treatment of acne patients with is-
otretinoin did not affect MMP-1 or TIMP but resulted in re-
duced activity of MMP-9 and secretion of MMP-13 in
sebum, an effect that was enhanced with the duration of
treatment and in parallel to the improvement of the clinical
picture. The effects of per os or topical administration of
isotretinoin on proMMP-9 of sebum samples that we ob-
served are in good agreement with reports that per os ad-
ministration of all-trans-RA to patients with emphysema
reduced plasma MMP-9 protein and activity, while having
little effect on TIMP-1 levels (Mao et al, 2003), and that
topical administration of retinol in healthy humans reduced
MMP-9 activity in punch biopsies of human buttock skin
(Varani et al, 2000).
The effects of isotretinoin in sebum MMP and TIMP fol-
lowing topical or systemic treatment of acne patients cor-
relate with the effects induced by isotretinoin in arachidonic
acid-treated HaCaT keratinocytes, which may better repre-
sent follicular keratinocytes of acne patients than HaCaT
keratinocytes not under inflammatory challenge. Isotretinoin
significantly inhibited the arachidonic acid-induced proM-
MP-2 and -9 and MMP-13 secretion by HaCaT keratin-
ocytes, although the latter was not statistically significant,
as well as the arachidonic acid-induced mRNA of MMP-9
and -13. In SZ95 sebocytes, isotretinoin also inhibited the
arachidonic acid-induced increase of proMMP-2 and -9
secretion, and the arachidonic acid-induced expression of
mRNA for MMP-9. The above-described effect of is-
otretinoin on MMP production by keratinocytes and se-
bocytes is in good agreement with studies on the effect of
RA on various cell cultures or tissues, which demonstrated:
(a) that all-trans-RA inhibited the activity of MMP-2 and -9 in
human arterial smooth muscle cells (Axel et al, 2001), the
activity of MMP-9 in human bronchoalveolar lavage cells
(Frankenberger et al, 2001), the activity of MMP-2 and -9 in
a rabbit model of vein bypass grafting (Leville et al, 2000),
and pro- and active MMP-9 protein in myelogenous le-
ukemia cell lines (Devy et al, 2002); (b) that retinol and all-
trans-RA decreased 98–96, 72–68, and 46–45 kDa gelatin-
olytic activity in capillary endothelial cells (Braunhut and
Moses, 1994); (c) that retinoids reduced the activation of
MMP in fibroblasts (Overall, 1995), and (d) that locally pro-
duced all-trans-RA suppresses MMP during endometrial
differentiation (Osteen et al, 2002). Similarly, the lack of any
effect of isotretinoin on TIMP secretion in sebum or in cell
cultures is in agreement with reports indicating that oral all-
trans-RA did not affect TIMP-1 in a rabbit model of vein
bypass grafting (Leville et al, 2000), and that it did not in-
fluence expression of TIMP-1 in human primary melanoma
(Jacob et al, 1998).
The inhibition of proMMP-9 following treatment with is-
otretinoin is not due to a direct inhibitory effect of the drug
on the enzyme, since isotretinoin, up to 1 mM, did not ex-
hibit any direct effect on proMMP-9 isolated from sebum
specimens of facial acne lesions or on commercially avail-
able gelatinases. The decrease in proMMP-9 and MMP-13
that we observed following treatment with isotretinoin may
be attributed to the reduction of the expression rate of these
MMP. This is in agreement with our observation that is-
otretinoin downregulated MMP-9 and -13 mRNA in HaCaT
keratinocytes and MMP-9 in SZ95 sebocytes. It is also
supported by reports that RA reduces the mRNA expres-
sion of MMP-2 and/or -9 in human arterial (Axel et al, 2001)
and rat aortic (Neuville et al, 1999) smooth muscle cells, in
tumor (Tsang and Crowe, 2001) and leukemia (Devy et al,
2002) cell lines, and in a rabbit model of vein bypass graft-
ing (Leville et al, 2000), whereas tretinoin reverses upreg-
ulation of MMP-13 in human keloid-derived fibroblasts
(Uchida et al, 2003).
The presence of MMP-9 activity and protein, and of col-
lagenases MMP-1 and -13 and TIMP protein of epithelial
origin in acne sebum, and the isotretinoin-induced decrease
of proMMP-9 and MMP-13 in parallel to the clinical im-
provement of the lesions indicate that these MMP and TIMP
may be involved in the pathophysiology of acne lesions,
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possibly by contributing to abnormal hyperproliferation, and
degradation and remodeling of extracellular matrix struc-
tures, such as the basement membrane of the acroinfundi-
bulum of the sebaceous follicle and the sebaceous glands.
Although the precise functional role of MMP and TIMP in
acne pathology remains to be clarified, it appears that the
isotretinoin-induced reduction in proMMP-9 and MMP-13,
via mechanisms that do not affect TIMP, may contribute to
the therapeutic effects of this agent in acne.
Materials and Methods
Patients Lesions in acne vulgaris patients ranged from clinically
non-inflammatory microcomedones, closed or open comedones,
to inflammatory papules, pustules, and cysts, intermingled to var-
ious extents. The criteria of the Global Alliance to Improve Out-
comes in Acne were used to classify acne into mild, moderate. and
severe (Gollnick et al, 2003). Fifty-nine female patients with acne
vulgaris, aged 17.8  1.7 y (mean  SD) were treated with topical
(0.05% once daily, 36 patients with mild and moderate papulo-
pustular acne) or systemic (1 mg per kg per d per os, 23 patients
with moderate nodular or severe acne) administration of is-
otretinoin for 3–4 mo, after providing their written consent. The
medical history of all patients was free from recent microbial in-
fections or any other disorders of the skin. Patients had not been
treated with retinoids in the past and were not under any other
medication for at least 3 mo prior to the initiation of the treatment in
this study. All patients were thoroughly informed about the adverse
effects of isotretinoin treatment and received other, but no hormo-
nal, contraception during and 3 mo after discontinuation of the
treatment. Participants gave their written informed consent. The
medical ethical committee of Aristotle University of Thessaloniki
has approved all the described studies. The study was conducted
according to the Declaration of Helsinki Principles.
Sebum samples Sebum from facial lesions, such as comedones,
papules, and pustules, were collected under standardized condi-
tions from individual acne lesions. Sebum collection was per-
formed using sterile, blunt, plastic ‘‘spatulas’’ to rupture the lesion
and gently squeeze out the sebum. Sebum was collected at the tip
of the spatula and transferred into sterile 1 mL Eppendorf plastic
vials. Samples were pooled in one plastic vial per individual patient,
per time point, and stored at 701C until use. Sebum sampling
was performed at three time points: prior to treatment (0 d sample),
31  3 d (30 d sample), and 63  4 d (60 d sample) after treatment
with isotretinoin. Aliquots of sebum samples, diluted to contain the
same amount of protein per mL, were analyzed in a blinded fashion
for the presence or absence of keratinocytes and/or bacteria. Light
microscopy of sebum samples was performed using an Olympus
BX50 microscope (Tokyo, Japan). Bacterial cultures of sebum
specimens obtained before and during treatment were performed
under strict aseptic techniques in Columbia blood agar and an-
aerobe blood agar. Bacteria were identified on the basis of mor-
phological and biochemical characteristics employing the VITEK
system (bioMerieux, Marcy l’Etoile, France). Identification was
confirmed by testing for various properties using tests according to
Murray et al (1999).
Cultures and treatment of HaCaT keratinocytes and SZ95 se-
bocytes Spontaneously immortalized, nontumorigenic human Ha-
CaT keratinocytes (Boukamp et al, 1988) (generously provided by
Prof. N. E. Fusenig and Dr D. Breitkreuz, German Cancer Research
Center, Heidelberg, Germany) and immortalized human facial SZ95
sebocytes (Zouboulis et al, 1999) were seeded at a concentration
of 3  104 cells per well in 24-well culture plates (Nunc, Wiesb-
aden, Germany) and were maintained in Sebomed medium (Bioch-
rom, Berlin, Germany) containing 10% (vol/vol) fetal calf serum,
5 ng per mL recombinant human epithelial growth factor, and
penicillin/streptomycin (all from Biochrom) at 5% CO2 and 371C.
Cells were cultured for 2 d in the presence or absence of arachi-
donic acid (Sigma-Aldrich, Deisenhofen, Germany), and dissolved
in ethanol to give a final arachidonic acid concentration of 104 M.
The final concentration of ethanol in medium without and with
arachidonic acid was 0.1%. Subsequently, cells were treated with
isotretinoin (Sigma-Aldrich) dissolved in dimethyl sulfoxide to give
final isotretinoin concentrations of 108 and 107 M. The final
concentration of dimethyl sulfoxide in medium without and with
isotretinoin was 0.2%. Isotretinoin was handled under dimmed
yellow light. Culture supernatants were collected after 12, 24, and
48 h of treatment with isotretinoin or DMSO into sealed plastic
tubes and frozen at 401C until further evaluation. Cells were also
collected separately after 48 h of treatment and stored under sim-
ilar conditions.
Gelatin zymography Gelatin zymography analysis was performed
in sebum specimens and medium of cell cultures, collected as
described above. In addition, gelatin zymography was performed
following in vitro experiments to test the effects of the agent on
gelatinases present in sebum as well as on commercially available
gelatinases. Sebum samples were suspended in 1 mL ddH2O and
subjected to ultrasonication in a Clifton Ultrasonic bath (Nickel-
Electro, Weston-Super-Mare, North Somerset, UK) (3  5 min) and
precipitation from saturation with 25%–50% (NH4)2SO4 at 41C
(Karakiulakis et al, 1988). For cell cultures, aliquots of the supe-
rnatants were diluted to contain the same amount of protein per
mL. The gelatinolytic activity of MMP was determined by gelatin
zymography analysis using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) under denaturing but non-reduc-
ing conditions (Karakiulakis et al, 1997). Molecular sizes of bands
displaying enzymatic activity were estimated in comparison with
purified proMMP-2 (72.0 kDa), active MMP-2 (64.0 kDa), proMMP-
9 (92.0 kDa) and active MMP-9 (68.0 kDa) (Anawa Trading, Wan-
gen). The pre-stained standard protein molecular weight markers
used were: phosphorylase b (97.4 kDa), bovine serum albumin
(66.2 kDa), L-glutamic dehydrogenase (55.0 kDa), ovalbumin
(42.7 kDa) and aldolase (40.0 kDa) (all from Promega, Madison,
WI). Gelatinolytic activity was quantified using a computer-assisted
image analysis program (1D Image Analysis Software, version 3.0
of Kodak Digital Science, Eastman Kodak, Rochester, New York).
The nature of the proteolytic bands was further characterized by
including specific protease inhibitors: Na2EDTA (20 mM), 1,10-
phenanthroline (4 mM), or N-ethyl-maleimide (5 mM) (all obtained
from Sigma-Aldrich) in the enzyme incubation buffer. The effect of
isotretinoin on 0 d sebum samples (corresponding to 5 mg protein)
or purified latent MMP-2 and -9 (1 ng protein) was studied by pre-
incubating samples with isotretinoin (0–1 mM) for 30 min at room
temperature, followed by gelatin zymography. SDS was then re-
moved from the gels by equilibrating (2  30 min) in 2.5% (vol/vol)
Triton X-100 (Sigma-Aldrich) and gels were incubated in enzyme
buffer (50 mM Tris-HCI, pH 7.3, containing 200 mM NaCI, 5 mM
CaCl2 and 0.1% Triton X-100), in the presence of isotretinoin (0–1
mM) for 18 h, at 371C.
Western blot analysis for determination of MMP Sebum sam-
ples, containing the same amount of total protein, were enriched in
MMP by precipitation with (NH4)2SO4 (60% saturation) (Karakiula-
kis et al, 1988); the resultant precipitates were dissolved in La-
emmli sample buffer containing 5% b-mercaptoethanol, boiled for
5 min, and then subjected to SDS-PAGE (Laemmli, 1970) on 10%
polyacrylamide gels. After electrophoresis, the separated proteins
were electro-transferred onto nitrocellulose membranes according
to the method of Towbin et al (1979). The free binding sites on the
nitrocellulose membranes were blocked with 5% skim milk in 20
mM Tris-HCl, pH 7.4/150 mM NaCl buffer (TBS), containing 0.05%
Tween-20 (TBS-T), at room temperature for 1 h. After three 10 min
washes with TBS-T, the membranes were incubated with rabbit
antiserum produced against human MMP-2 or MMP-9, (a gener-
ous gift from Dr. P. Koolwijk, Gaubius Lab. TNO-PG, the Nether-
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lands) (Hanemaaijer et al, 1998), or affinity purified anti-rabbit po-
lyclonal AB806 for MMP-1 and AB8114 for MMP-13 (Chemicon
International, Temecula, California), at dilution 1:1000, in TBS-T,
containing 1% skim milk, at 41C for 20 h. After washing three times
with TBS-T, they were incubated with peroxidase-conjugated goat
anti-rabbit IgG at dilution 1:4000 in TBS-T, containing 1% skim
milk, at room temperature for 2 h. Then, the membranes were
washed with TBS-T three times, once with TBS and the immuno-
reacted proteins were detected by the enhanced chemilumines-
cence method, according to the manufacturer’s instructions
(Pierce, Rockford, Illinois). For negative controls, nitrocellulose
membranes were subsequently treated with stripping solution
(Chemicon). After stripping, membranes were re-blocked, as de-
scribed above, and incubated with rabbit anti-ovalbumin IgG
(Chemicon) (instead of the specific rabbit antibodies for MMP), at
dilution 1:1000, in TBS-T, containing 1% skim milk, at 41C for 20 h.
Subsequent steps were as described above. When the non-
specific antibody was used, no immunoreactive bands could be
detected for any MMP examined. Quantification of chemilumines-
cence was performed using a computer-assisted image analysis
program (1D Image Analysis Software, version 3.0 of Kodak Digital
Science). Molecular size was estimated by comparison prestained
standard proteins: phosphorylase b (97.4 kDa), bovine serum al-
bumin (66.2 kDa), ovalbumin (45.0 kDa) and soybean trypsin in-
hibitor (21.5 kDa) (all from Promega, Madison, Wisconsin), which
were electrophoresed under reducing conditions.
ELISA for determination of collagenases and TIMP MMP-1 and
-13 were determined in aliquots of sebum samples or the supe-
rnatants of cell cultures by ELISA. Samples were enriched in MMP
by precipitation with (NH4)2SO4 (60% saturation) (Karakiulakis et al,
1988) and assayed for MMP-1 and -13 as previously described
(Papakonstantinou et al, 2003), using anti-MMP-1 (1 mg per mL, Ab
806, Chemicon) or anti-MMP-13 (1 mg per mL, Ab 8114, Chemicon)
polyclonal antibodies in PBS-T and peroxidase-conjugated second
antibody (goat anti-rabbit IgG, Chemicon). The concentration of
collagenases was estimated in pg collagenase protein per mg of
total protein per sebum sample, using reference samples of MMP-
1 and -13 from human periprosthetic tissue of loose hip endo-
prostheses (Syggelos et al, 2001). TIMP-1 and -2 were measured in
aliquots of sebum samples or the supernatants of cell cultures,
using ELISA systems (Biotrak RPN 2611 for TIMP-1 and Biotrak
RPN 2618 for TIMP-2; Amersham Pharmacia, Freiburg, Germany)
that recognize total human TIMP-1 or -2, both free and that com-
plexed with MMP.
RT-PCR for expression of MMP and TIMP-1 Isolation of RNA
was performed by the RNeasy spin mini kit (Qiagen, Hilden, Ger-
many), according to the manufacturer’s instructions. Gene expres-
sion of MMP and TIMP-1 was ascertained by semi-quantitative RT-
PCR analysis according to Papakonstantinou et al (2004), adjusted
as follows: total RNA (50 ng for MMP-1, 400 ng for MMP-13, 200
ng for MMP-2, 200 ng for MMP-9, 20 ng for TIMP-1, and 10 ng for
GAPDH) was added to each RT reaction containing one-step RT-
PCR mix (Robus I, Finnzymes, Espoo, Finland) and the appropriate
PCR primers (15 pmole) in 50 mL total volume. Reverse transcrip-
tion was carried out for 30 min at 501C, followed by a 2 min step at
941C. PCR was then performed on a PTC-100 programmable
Thermal Controller (MJ Research, Waltham, Massachusetts), pro-
grammed for several cycles of 1 min at 941C, 1 min at optimal
annealing temperature, and 1 min at 721C, followed by a 10 min
step of extra extension at 721C. The amount of total RNA used, as
well as the number of PCR cycles, was adjusted so that each PCR
amplification was in the linear range. Primers for MMP-1 (428 bp,
annealing at 551C, 30 cycles, Konttinen et al, 1999), MMP-2 (605
bp, annealing at 581C, 40 cycles, Giambernardi et al, 1998), MMP-
9 (519 bp, annealing at 551C, 30 cycles, Moore et al, 2000), MMP-
13 (517 bp, annealing at 531C, 35 cycles, Moore et al, 2000), and
TIMP-1 (534 bp, annealing at 601C, 30 cycles, Moore et al, 2000)
were obtained from MWG-Biotech AG (Ebersberg, Germany). Am-
plification specific for GAPDH (MWG-Biotech AG) (263 bp, an-
nealing at 611C, 30 cycles) was used to estimate the efficiency of
the reverse transcription reaction for MMP and TIMP-1. Five mi-
croliters of each PCR reaction mixture were analyzed in a 2%
agarose gel, using a 100 bp DNA ladder (Invitrogen, Life
Technologies, Carlsbad, California). Visualization of DNA bands
was achieved with UV illumination of ethidium bromide-stained
gels. Quantification of chemiluminescence was performed using a
computer-assisted image analysis program (1D Image Analysis
Software, version 3.0 of Kodak Digital Science Eastman Kodak).
Analysis of MMP and TIMP expression by cDNA microar-
rays SZ95 sebocytes were maintained under the conditions de-
scribed above without arachidonic acid and isotretinoin for 120 h.
Subsequently, RNA extraction was performed using the RNeasy
Midi kit (Qiagen) according to the manufacturer’s protocol. RNA
was photometrically measured in a Pharmacia GeneQuant II spec-
trophotometer (Freiburg, Germany) and stored at 801C until use.
Amplified RNA (aRNA) was generated from 3 mg of DNase 1-treat-
ed total RNA using the MegaScript T7 High Yield Transcription kit
(Ambion, Austin, Texas). RNA purity, integrityand concentrations
were evaluated on the Agilent 2100 bioanalyzer. Cy3- and Cy5-
labelled cDNA was reverse transcribed from 3 mg of aRNA per
reaction. All labeling reactions used the Cyscribe First-Strand
cDNA labeling Kit (Amersham Pharmacia). Purification of labeled
cDNA was carried out using Microcon YM-30 columns (Millipore,
Billerica, Massachusetts). Four replicated hybridizations consisting
of duplicated dye swaps were carried out on the Human ENSEMBL
chip using protocols described previously (Adjaye et al, 2004). The
cDNA microarray consists of 15,500 non-redundant, fully se-
quenced, annotated human cDNA (Human Ensembl set RZPD1.1)
spotted in duplicate on superAmine-coated glass slides (Telechem,
Sunnyvale, California) with each slide containing positive/internal
controls (b-actin, HPRT), and a selection of Arabidopsis cDNA as
negative controls. Slides were scanned using the Affymetrix 428
Array Scanner (Santa Clara, California).
Data analysis of cDNA microarrays Image analysis was carried
out with the AIDA Array Matrix software (Raytest, Straubenhardt,
Germany). In total, 11 replicate experiments were carried out. Data
were normalized as described in Herwig et al (2001). In order to
judge whether a given gene was expressed in SZ95 sebocytes, for
each experiment, the signal of the gene was compared with a
reference distribution derived from 3626 negative control signals
by computing the proportion of negative spots having a smaller
signal than the gene of interest. The average proportion across all
replicates was defined as the ‘‘expression probability’’ for the gene
and was used as an indicator for the expression strength in SZ95
sebocytes. Visual inspection of hybridization images indicates that
a high probability (p40.95) corresponds to visible signals, whereas
spots with po0.9 correspond to absent signals. Probabilities in
between correspond to weakly expressed signals.
Protein measurement Protein content was determined in aliquots
of sebum specimens, aliquots of cell culture supernatants and cells
with the standard Bradford assay (Bio-Rad, Glattbrugg, Switzer-
land) using bovine serum albumin (Sigma-Aldrich Chemie, Stein-
heim, Germany) as standard. All data presented were normalized
per protein content for each sebum or cell culture specimen.
Statistical analysis Where relevant, data are presented as mean
 SD. Differences between means were evaluated by anal-
ysis of variance. po0.05 was considered statistically significant.
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